Significance of post-progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma.

Yoshihiko YanoAtsushi YamamotoAkihiro MinamiKenji MomoseTakuya MimuraSoo Ki KimHiroki HayashiTakuo KadoHirotaka HiranoSeiya HirohataSeitetsu YoonKatsuhisa NishiHiroshi TeiHidenori TanakaSachiko OouchiTakanori MatsuuraEiichiro YasutomiYuri HatazawaYuuki ShiomiYoshihide UedaYuzo Kodamanull null

Published in: JGH open : an open access journal of gastroenterology and hepatology (2022)

The introduction of newer drugs for post-progression therapy is expected to prolong survival. ICI-based regimens appear to be effective after lenvatinib.

Keyphrases

cell therapy
free survival
bone marrow
drug induced
chronic myeloid leukemia